Novaccess Global Inc XSNX

Healthcare Biotechnology

NovAccess Global Inc. is a biopharmaceutical company, which develops immunotherapies to treat brain tumor patients in the United States. The Company specializes in research related to utilizing a patient’s own immune system to attack the cancer. Its dendritic cell-based immunotherapy utilizes a combination of Toll-like receptor adjuvants for an enhanced antitumor response. The therapy is designed to utilize the patient’s tumor antigens and immune cells, dendritic cells, in combination with TLR adjuvants to initiate an efficient antitumor immune response. This process includes obtaining the patients' tumor cells after surgery, and precursors cells that are matured into dendritic cells from peripheral blood. Its TLR-AD1 platform technology is a vaccine immunotherapy for the treatment of aggressive brain cancers, including glioblastoma and other high-grade gliomas. TLR-AD1 technology has a scope of use and is embodied in various different product lines for different clinical situations.

OTCPK:XSNX - Post by User

Novaccess Global Inc

Bullboard Posts

Comment by dondonon Jan 15, 2006 3:50pm

139 Views

Post# 10178216

RE: XSunX

what took you so long "shorter",hey folks take a look hit his name this is his first post,probably gonna see him bash this stock,this "distorter"borrowed a few too many shares,missread fri and now has a big price to pay,probably shorted at.78,well looks like shorters will have to wait before borrowing more shares ie $1.25,Mon gonna see them scrambling to cover:gotta luv it when theyre caught with their shorts up" Mac